

1. Morgenstern DA, Pötschger U, **Moreno L**, Papadakis V, Owens C, Ash S, Pasqualini C, Luksch R, Garaventa A, Canete A, Elliot M, Wieczorek A, Laureys G, Kogner P, Malis J, Ruud E, Beck-Popovic M, Schleiermacher G, Valteau-Couanet D, Ladenstein R. Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study. *Pediatr Blood Cancer*. 2018 Nov;65(11):e27363. doi: 10.1002/pbc.27363. Epub 2018 Jul 17.
2. **Moreno L**, Casanova M, Chisholm JC, Berlanga P, Chastagner PB, Baruchel S, Amoroso L, Gallego Melcón S, Gerber NU, Bisogno G, Fagioli F, Geoerger B, Glade Bender JL, Aerts I, Bergeron C, Hingorani P, Elias I, Simcock M, Ferrara S, Le Bruchec Y, Slepetic R, Chen N, Vassal G. Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer. *Eur J Cancer*. 2018 Sep;100:27-34. doi: 10.1016/j.ejca.2018.05.002. Epub 2018 Jun 21. PubMed PMID: 29936064
3. **Moreno L**, Caron H, Geoerger B, Eggert A, Schleiermacher G, Brock P, Valteau-Couanet D, Chesler L, Schulte JH, De Preter K, Molenaar J, Schramm A, Eilers M, Van Maerken T, Johnsen JI, Garrett M, George SL, Tweddle DA, Kogner P, Berthold F, Koster J, Barone G, Tucker ER, Marshall L, Herold R, Sterba J, Norga K, Vassal G, Pearson AD. Accelerating drug development for neuroblastoma – New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. *Expert Opin Drug Discov*. 2017 Aug;12(8):801-811. doi: 10.1080/17460441.2017.1340269. Epub 2017 Jun 26. Review. PubMed PMID: 28604107.
4. Basta NO, Halliday GC, Makin G, Birch J, Feltbower R, Bown N, Elliott M, **Moreno L**, Barone G, Pearson AD, James PW, Tweddle DA, McNally RJ. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma. *Br J Cancer*. 2016 Oct 25;115(9):1048-1057. doi:10.1038/bjc.2016.302. Epub 2016 Oct 4. PubMed PMID: 27701387; PubMed Central PMCID: PMC5117794.
5. **Moreno L**, Pearson ADJ, Paoletti X, Jimenez I, Geoerger B, Kearns PR, Zwaan CM, Doz F, Baruchel A, Vormoor J, Casanova M, Pfister SM, Morland B, Vassal G; Innovative Therapies for Children with Cancer (ITCC) Consortium. Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective. *Nat Rev Clin Oncol*. 2017 Aug;14(8):497-507. doi:10.1038/nrclinonc.2017.59. Epub 2017 May 16. Review. PubMed PMID: 28508875
6. **Moreno L**, Rubie H, Varo A, Le Deley MC, Amoroso L, Chevance A, Garaventa A, Gambart M, Bautista F, Valteau-Couanet D, Geoerger B, Vassal G, Paoletti X, Pearson AD. Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials. *Pediatr Blood Cancer*. 2017 Jan;64(1):25-31. doi: 10.1002/pbc.26192. Epub 2016 Aug 24. PubMed PMID: 27555472
7. Carceller F, Bautista FJ, Jiménez I, Hladun-Álvaro R, Giraud C, Bergamaschi L, Dandapani M, Aerts I, Doz F, Frappaz D, Casanova M, Morland B, Hargrave DR, Marshall LV, Vassal G, Pearson AD, Geoerger B, **Moreno L**. Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe: An Innovative Therapies for Children with Cancer study. *Eur J Cancer*. 2016 Nov;67:130-140. doi: 10.1016/j.ejca.2016.08.008. Epub 2016 Sep 21. PubMed PMID: 27662616

8. **Moreno L** & Smith J (Joint first), Heaton SP, Chesler L, Pearson ADJ, Garrett MD. Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma. *Mol Oncol* 2016 Apr;10(4):538-52. doi: 10.1016/j.molonc.2015.11.005. Epub 2015 Nov 19. PubMed PMID: 26686971; PubMed Central PMCID: PMC5423144.
9. Schrey D, Vaidya S, Levine D, Pearson ADJ, **Moreno L**, Additional therapies to improve metastatic response to induction therapy in children with high risk neuroblastoma, *J Pediatr Hematol Oncol* 2015 Apr;37(3):e150-3.
10. **Moreno L**, Marshall LV, Pearson ADJ, At the frontier of progress for paediatric oncology: the neuroblastoma paradigm. *Br Med Bull* 2013; 108: 173-88
11. Barone G, Tweddle DA, Shohet J, Chesler L, **Moreno L**, Pearson ADJ, van Maerken T. MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance. *Curr Drug Targets* 2014 Jan 5 Epub ahead of print
12. **Moreno L**, ALK targeted therapy for poor prognosis childhood cancers. *Lancet Oncol* 2013, May;14(6):439-40.

Moreno L, Vaidya SJ, Pinkerton CR, Lewis IJ, Imeson J, Machin D, Pearson ADJ. Long term follow-up of children with high risk neuroblastoma: The ENSG5 trial experience. *Pediatr Blood & Cancer* 2013; 60(7): 1135-40